ADC Therapeutics SA Key Management Personnel Compensation Postemployment Benefits
ADC Therapeutics SA (ADCT) reported Key Management Personnel Compensation Postemployment Benefits of $17.00 thousand for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits · last filed 2023-11-07
- ADC Therapeutics SA key management personnel compensation postemployment benefits for the quarter ending 2023-09-30 was $17.00K, a 63.83% decline year-over-year.
- ADC Therapeutics SA key management personnel compensation postemployment benefits for the quarter ending 2023-06-30 was $36.00K, a 49.30% decline year-over-year.
- ADC Therapeutics SA key management personnel compensation postemployment benefits for the quarter ending 2023-03-31 was $195.00K, a 46.62% increase year-over-year.
- ADC Therapeutics SA key management personnel compensation postemployment benefits for the quarter ending 2022-12-31 was $175.00K, a 68.27% increase year-over-year.
| Period end | Key Management Personnel Compensation Postemployment Benefits 3 month | Key Management Personnel Compensation Postemployment Benefits 6 month | Key Management Personnel Compensation Postemployment Benefits 9 month | Key Management Personnel Compensation Postemployment Benefits 12 month |
|---|---|---|---|---|
| 2023-09-30 | $17.00K 6-K · filed 2023-11-07 | $53.00K derived: sum of 2 quarters · filed 2023-11-07 | $248.00K 6-K · filed 2023-11-07 | $423.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $36.00K 6-K · filed 2023-08-08 | $231.00K 6-K · filed 2023-08-08 | $406.00K derived: sum of 3 quarters · filed 2023-08-08 | $453.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $195.00K 6-K · filed 2023-05-09 | $370.00K derived: sum of 2 quarters · filed 2023-05-09 | $417.00K derived: sum of 3 quarters · filed 2023-11-07 | $488.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $175.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $222.00K derived: sum of 2 quarters · filed 2023-11-07 | $293.00K derived: sum of 3 quarters · filed 2023-11-07 | $426.00K 20-F · filed 2023-03-15 |
| 2022-09-30 | $47.00K 6-K · filed 2023-11-07 | $118.00K derived: sum of 2 quarters · filed 2023-11-07 | $251.00K 6-K · filed 2023-11-07 | $355.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $71.00K 6-K · filed 2023-08-08 | $204.00K 6-K · filed 2023-08-08 | $308.00K derived: sum of 3 quarters · filed 2023-08-08 | $406.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $133.00K 6-K · filed 2023-05-09 | $237.00K derived: sum of 2 quarters · filed 2023-05-09 | $335.00K derived: sum of 3 quarters · filed 2023-05-09 | $441.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $104.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $202.00K derived: sum of 2 quarters · filed 2023-03-15 | $308.00K derived: sum of 3 quarters · filed 2023-03-15 | $442.00K 20-F · filed 2023-03-15 |
| 2021-09-30 | $98.00K 6-K · filed 2022-11-08 | $204.00K derived: sum of 2 quarters · filed 2022-11-08 | $338.00K 6-K · filed 2022-11-08 | $431.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $106.00K 6-K · filed 2022-08-09 | $240.00K 6-K · filed 2022-08-09 | $333.00K derived: sum of 3 quarters · filed 2023-03-15 | $439.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $134.00K 6-K · filed 2022-05-09 | $227.00K derived: sum of 2 quarters · filed 2023-03-15 | $333.00K derived: sum of 3 quarters · filed 2023-03-15 | $440.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $93.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $199.00K derived: sum of 2 quarters · filed 2023-03-15 | $306.00K derived: sum of 3 quarters · filed 2023-03-15 | $455.00K 20-F · filed 2023-03-15 |
| 2020-09-30 | $106.00K 6-K · filed 2021-11-02 | $213.00K derived: sum of 2 quarters · filed 2021-11-02 | $362.00K 6-K · filed 2021-11-02 | |
| 2020-06-30 | $107.00K 6-K · filed 2021-08-03 | $256.00K 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $149.00K 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $407.00K 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $299.00K 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |